Apogee Therapeutics, Inc. - Common Stock —— 资产负债表 (NASDAQ:APGE) | MetaTrader

展开完整图表完整图表

Financials

概览声明统计

每季度年度

新闻

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-05-30

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE)

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Blackstone Backs Apogee With Up To $1.3 Billion

Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE)

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Why Delta, Starbucks and these other stocks were just added to a market-beating ‘fresh money’ list

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE)

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23